Drug
Mosunetuzumab
Mosunetuzumab: highest development phase Phase 2, developed by Roche. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mosunetuzumab NCT07598396 | Phase 2 | Lupus |
| Mosunetuzumab NCT03677141 | Phase 1/2 | B-cell Non-Hodgkin Lymphoma |
| Mosunetuzumab NCT05091424 | Phase 1 | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Latest
No recent events.
Follow Mosunetuzumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.